
Next generation
full-body embolic
protection for TAVI

Cardiovascular data presented at EuroPCR 2022 demonstrates successful device performance during a TAVR procedure with no complications.
FILTERLEX
THE NEED
During catheter-based, left-heart procedures such as TAVI, embolic particles are often released to the blood flow. Particles migration to the brain may cause a spectrum of neurological deficiencies, from cognitive impairment to debilitating stroke. Emboli released to distal organs may result in acute kidney injury and ischemia.
CAPTIS®
CAPTIS® UNIQUE BENEFITS

Full-body embolic protection

Embolic capture and extraction

Easy and intuitive deployment and retrieval

Aortic surface protection

Fully integrates with the procedure

No interference to procedure devices

Stable and safe anchoring

Very stable aortic arch deflector

Accommodates anatomical variations
NEWS
June 2 - 2022
Cardiovascular data presented at EuroPCR 2022 demonstrates successful device performance during a TAVR procedure with no complications.
May 10 - 2022
Cardiovascular study results to be presented by Prof. Ran Kornowski, Director of the Cardiology Center, Rabin Medical Center at the EuroPCR 2022 conference in May
Dec 21 - 2021
Equity investment to support advancement of its breakthrough full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures.
Nov 18 - 2021
The financing will accelerate implementation of the company’s CAPTIS® clinical program
July-August 2021 - Vol. 8, No. 7.
Deflection and Capture Provides Full-Body Protection.
Sep 16 - 2019
€2.1M Grant to support Filterlex’s CAPTIS clinical trials
Best Innovation Award at the EuroPCR
May 6 - 2019
Filterlex receives the Best Innovation Award at the EuroPCR 2019 for the CAPTIS Embolic Protection Device for TAVI.
THE TEAM

This project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement No 881076